The U.S. Food and Drug Administration approved Eli Lilly and Co's treatment...
FILE PHOTO: The logo of Lilly is seen on a wall of the Lilly France company unit, part of the Eli Lilly and Co drugmaker group, in Fegersheim near Strasbourg, France, February 1, 2018. REUTERS/Vincent Kessler
- The U.S. Food and Drug Administration approved Eli Lilly and Co’s treatment for severe hypoglycemia, the health regulator said on Wednesday.Severe hypoglycemia typically occurs in people with diabetes who are using insulin treatment, the FDA said and noted that the therapy - Baqsimi - is approved to treat the severe form of the condition in patients with diabetes aged four and older.
Baqsimi is a powder that is administered into the nose. It is the first glucagon therapy approved for the emergency treatment of the condition, without using an injection, the agency said. “This new way to administer glucagon may simplify the process, which can be critical during an episode,” said Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research.
“The U.S. list price for a Baqsimi one-pack is $280.80 and $561.60 for a two-pack,” the company said in a statement, adding that Baqsimi is expected to be available in U.S. pharmacies within a month.Reporting by Aakash Jagadeesh Babu in Bengaluru, Additional reporting by Maria Ponnezhath; Editing by Bernard Orr and Sherry Jacob-Phillips
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA issues warning to Curaleaf for 'illegally selling' CBD products with 'unsubstantiated claims'The Food and Drug Administration issued a warning letter to Curaleaf for allegedly 'illegally selling' CBD products with 'unsubstantiated claims' like the products treating cancer, Alzheimer's disease, opioid withdrawal, pain and pet anxiety.
Read more »
Allergan Recalls Breast Implants After FDA Cites Lymphoma LinkAllergan recalled certain textured breast implants from the market after U.S. health regulators said there was an increase in cases of a rare type of cancer and deaths among women receiving the implants.
Read more »
FDA asks Allergan to recall textured breast implants worldwideAllergan Plc said on Wednesday it was recalling its Biocell textured breast impl...
Read more »
FDA Now Wants Textured Breast Implants to Be RecalledAlmost three months after the Food and Drug Administration chose not to enact a wholesale ban of textured breast implants—a type of implant linked to a rare cancer—the agency has asked the breast implant maker Allergan to recall its textured implants currently available in the United States. According to the FDA, Allergan is “moving forward with a worldwide recall.”
Read more »